More articles from Letters to the Editor

  • In Reply: Prostate cancer screening
    Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 261; DOI: https://doi.org/10.3949/ccjm.88c.05003

    Detection does not lead to overtreatment.

  • Prostate cancer screening
    Sherry Zhang, MD and Ian Jenkins, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05001

    The costs of PSA testing—both financial and to the patient’s well-being—are not worth it.

  • Prostate cancer screening
    Kevin Kurator, BS, BA and Ian Jenkins, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05002

    Screening should be advised only if benefits clearly outweigh the risks

  • In Reply: Prostate cancer screening
    Timothy Gilligan, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 262; DOI: https://doi.org/10.3949/ccjm.88c.05004

    The debate about screening remains fraught, and passions run high on both sides.

  • Assessing stable coronary artery disease
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 713; DOI: https://doi.org/10.3949/ccjm.87c.12003

    Differences between the coronary calcium score and CT coronary angiography

  • Dexamethasone or hydrocortisone in COVID-19?
    Chia Siang Kow, and Syed Shahzad Hasan,
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 715; DOI: https://doi.org/10.3949/ccjm.87c.12005

    Dexamethasone should be favored over hydrocortisone.

  • In Reply: Assessing stable coronaryartery disease
    Vinayak Nagaraja, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 714; DOI: https://doi.org/10.3949/ccjm.87c.12004

    CT angiography is the appropriate test to exclude left main disease.

  • In Reply: COVID-19 coagulopathy
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/cjm.87c.12002

    An attempt to balance the potential risks and benefits of intensified prophylaxis.

  • COVID-19 coagulopathy
    Anup Katyal, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/ccjm.87c.12001

    Skepticism of high-intensity prophylaxis for patients with D-dimer ≥ 3.0 µg/mL.

  • Trousseau sign and syndrome: Erroneous terms
    Steven Yale, MD, MACP, Halil Tekiner, PhD, Joseph Mazza, MD and Eileen Scott Yale, MD
    Cleveland Clinic Journal of Medicine October 2020, 87 (10) 585; DOI: https://doi.org/10.3949/ccjm.87c.10002

    Trousseau never described a constellation of symptoms in this disease.

Pages